LONDON – Studies have shown that marijuana not only helps fight the symptoms of treating cancer but also the disease itself. THC, or tetrahydrocannabinol, often gets the credit for battling cancer cells, but a new study shows that THC isn’t working alone. The study conducted at St. George’s University of London, led by Dr. Wai Liu, examined six […]
Read More Anti-Cancer Properties of Medical Marijuana Revealed in its entirety on The Daily Chronic.
Want to stay up to date on marijuana reform & cannabis news worldwide? Visit The Daily Chronic - The Voice of the Reform Generation, the most comprehensive coverage of the cannabis community!READ MORE
AUGUSTA, ME – Patients diagnosed with post-traumatic stress, Crohn’s disease, and other debilitating disorders will soon be eligible for cannabis therapy under legislation approved last week absent the Governor’s signature.
The new law expands the list of qualifying conditions for which a Maine physician may legally recommend cannabis to include “post-traumatic stress disorder,” “inflammatory bowel disease” (such as Crohn’s and/or ulcerative colitis), and “dyskinetic and spastic movement disorders and other diseases causing severe and persistent muscle spasms” (such as Parkinson’s disease and/or Huntington’s disease). It is the second time that Maine legislators have acted to expand the pool of patients who may have access to medicinal cannabis.
The law takes effect in approximately 90 days.
Four states — Connecticut, Delaware, New Mexico, and Oregon — explicitly allow for the use of cannabis to treat symptoms of post-traumatic stress.
Inhaling cannabis reduces symptoms of Crohn’s disease compared to placebo in patients non-responsive to traditional therapies, according to clinical trial data published online ahead of print in the journal Clinical Gastroenterology and Hepatology.
Researchers at the Meir Medical Center, Department of Gastroenterology and Hepatology in Israel assessed the safety and efficacy of inhaled cannabis versus placebo in 21 subjects with Crohn’s disease who were nonresponsive to conventional treatments.
Eleven participants smoked standardized cannabis cigarettes containing 23 percent THC and 0.5 percent CBD (cannabidiol) twice daily over a period of eight weeks. The other ten subjects smoked placebo cigarettes containing no active cannabinoids.
Investigators reported, “Our data show that 8-weeks treatment with THC-rich cannabis, but not placebo, was associated with a significant decrease of 100 points in CDAI (Crohn’s Disease and activity index) scores.” (The CDIA is a research tool used to quantify the symptoms of Crohn’s disease patients.) Five of the eleven patients in the study group also reported achieving disease remission (defined as a reduction in pat. . . . . READ MORE